1. Bioorg Med Chem Lett. 2015 Oct 15;25(20):4412-8. doi: 
10.1016/j.bmcl.2015.09.018. Epub 2015 Sep 8.

Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An 
empirical brain-exposures-driven candidate selection for in vivo efficacy 
studies.

Devasthale P(1), Wang W(2), Mignone J(2), Renduchintala K(3), Radhakrishnan 
S(3), Dhanapal J(3), Selvaraj J(3), Kuppusamy R(3), Pelleymounter MA(4), Longhi 
D(4), Huang N(4), Flynn N(4), Azzara AV(4), Rohrbach K(4), Devenny J(4), Rooney 
S(4), Thomas M(4), Glick S(4), Godonis H(4), Harvey S(4), Cullen MJ(4), Zhang 
H(5), Caporuscio C(5), Stetsko P(4), Grubb M(4), Huang C(4), Zhang L(4), Freeden 
C(4), Murphy BJ(4), Robl JA(2), Washburn WN(2).

Author information:
(1)Metabolic Diseases Chemistry, Bristol-Myers Squibb Research and Development, 
Princeton, NJ 08543-5400, United States. Electronic address: 
pratik.devasthale@bms.com.
(2)Metabolic Diseases Chemistry, Bristol-Myers Squibb Research and Development, 
Princeton, NJ 08543-5400, United States.
(3)BMS-Biocon Research Center, Biocon, 20th KM, Hosur Road, Electronic City, 
Bangalore 560 100, India.
(4)Metabolic Diseases Biology, Bristol-Myers Squibb Research and Development, 
Princeton, NJ 08543-5400, United States.
(5)Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and 
Development, Princeton, NJ 08543-5400, United States.

Non-basic azolotriazinones were explored using an empirical free brain 
exposures-driven approach to identify potent MCHR1 antagonists for evaluation in 
in vivo efficacy studies. An optimized lead from this series, 1j (rMCHR1 Ki=1.8 
nM), demonstrated a 6.9% reduction in weight gain relative to vehicle in a rat 
model at 30 mg/kg after 4 days of once-daily oral treatment as a glycine 
prodrug. Despite a promising efficacy profile, an assessment of the biliary 
toxicity risk of this compound rendered this compound non-progressible.

Copyright Â© 2015 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.bmcl.2015.09.018
PMID: 26386604 [Indexed for MEDLINE]
